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Abstract
Background: Malignant struma ovarii is an ovarian teratoma containing at least 50% thyroid tissue which has the
potential to metastasize and produce thyroid hormone. Given its rarity, management strategies are not well-
established. We report a case of metastatic malignant struma ovarii discovered during pregnancy with lessons for
evaluation and management.
Case presentation: A 30-year-old woman who was two months pregnant was discovered to have struma ovarii
with over half of the struma comprised of papillary thyroid cancer. Following tumor resection, delivery, and
thyroidectomy, she underwent evaluation with stimulated thyroglobulin testing and diagnostic staging sodium
iodide-131 scan (I-131), which revealed the presence of skeletal metastases. Following administration of 320 mCi I-
131, post-therapy scan also showed miliary pulmonary metastases with improved ability to localize the bony and
pulmonary metastases with concurrent SPECT/CT imaging. A second dosimetry-guided I-131 therapy resulted in
complete resolution of pulmonary metastases; however, small foci of residual bone disease persisted. Post-therapy
scans demonstrated additional findings not shown on diagnostic I-131 scans obtained prior to both her initial and
second I-131 therapy.
Conclusions: SPECT/CT provides accurate anatomic correlation and localization of metastatic foci and can serve as
a baseline study to assess interval response to treatment. Post-therapy scans should always be obtained when I-131
treatment is administered, as additional findings may be revealed versus low dose I-131 activity diagnostic scans.
This patient had a high metastatic burden that would not have been discovered in a timely fashion with the
conservative approach advocated by others. Thyroidectomy followed by a diagnostic staging radioiodine scan and
a stimulated thyroglobulin level should be considered in patients with malignant struma ovarii for guiding
therapeutic I-131 administration as metastatic risk is difficult to predict based on histopathologic examination.
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Background
Struma ovarii is a rare form of ovarian teratoma (ovarian
dermoid cyst) that contains greater than 50% thyroid tis-
sue, accounting for less than 1% all ovarian tumors [1].
Hyperthyroidism is present in 5–8% of cases, while thy-
roid cancer is uncommon, representing less than 5% of
all struma [1, 2] with distant metastases being reported
in 5–23% of patients with malignant struma ovarii [3].
The pathologic diagnosis of malignant transformation
within ovarian dermoid cysts is challenging as the histo-
logic criteria for cancer within the thyroid gland may not
be predictive of metastatic potential in struma ovarii [4].
The diagnostic criteria and management strategies are
controversial owing to the rarity of this condition and lack
of reliable predictive factors regarding metastatic poten-
tial. We present the case of a patient diagnosed with ma-
lignant struma ovarii during pregnancy and how a more
aggressive approach was beneficial. We highlight the ben-
efits of diagnostic radioiodine scintigraphy with single
photon emission computed tomography/computed tom-
ography (SPECT/CT) for completion of staging and for
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guiding sodium iodide-131 (I-131) treatment based on
dosimetry calculations. We also discuss the importance of
post-therapy I-131 scans for assessing disease burden and
present the follow-up strategy used for ascertaining thera-
peutic response. The role of estrogen, progesterone, and
human chorionic gonadotropin (hCG) stimulation in thy-
roid cancer is also reviewed.
Case presentation
A 30-year old woman presented with two weeks of left
lower quadrant discomfort during her second month of
pregnancy. Ultrasound revealed a mixed cystic and solid
left adnexal mass measuring 8.6 × 6.7 × 8.3 cm. Left
salpingo-oophorectomy was performed early in the sec-
ond trimester. Grossly, the left ovary demonstrated an
intact 7.5 cm complex cystic-solid mass, with nearly half
involved by a friable, tan-yellow tumor with papillary ex-
crescences, some of which were freely floating within
the cyst cavity. Histologic sections demonstrated a
struma ovarii with over 50% characterized by the classic
features of a well-differentiated papillary thyroid carcin-
oma (Fig. 1A). The periphery of the tumor impinged on
the ovarian capsule and vascular structures; however, no
definitive evidence of invasion was seen on the histologic
sections reviewed (Fig. 1B-C). Typical histology for an
ovarian mature cystic teratoma (such as areas of squa-
mous differentiation) were present in other areas of the
tumor (Fig. 1D). The tumor expressed positive immuno-
histochemical staining for thyroglobulin (Tg) and thyroid
transcription factor 1 (TTF1, Fig. 1E), but was negative
for BRAF V600E. Serum Tg was 83.5 ng/mL (reference
range for euthyroid status in nonpregnant adults 0–
35 ng/mL) seven days after surgical resection of the
ovarian mass. The elevated Tg level is reasonably ex-
pected given the proximity to surgery and Tg half-life of
65 h [5] and the known increase in Tg levels during
pregnancy [6, 7]. Thyroid function tests (TSH 1.66 mU/
L) and thyroid ultrasound were normal. Levothyroxine
(L-T4) was started to suppress thyroid stimulating hor-
mone (TSH) to 0.1–0.5 mU/L although TSH ranged
0.86–1.41 mU/L during pregnancy. After delivery, Tg
was 2.9 ng/mL (TSH 0.57 mU/L). With thyroglobulin
levels in a reasonable range as above, the risk of add-
itional studies during pregnancy in terms of radiation or
hypothyroid exposure, unknown risk of metastatic dis-
ease, and unknown incremental benefit of intervention
Fig. 1 Histologic sections of malignant struma ovarii. Areas of adenomatous differentiation (a - lower right) and classic papillary thyroid
carcinoma (a - center left) with papillary growth and cleared out “orphan Annie” nuclei. Area of Hurthle cell differentiation (a – center right) with
an illustrative mitosis (a – inset). Tumor proliferation impinging on vascular structures (b). While the irregular border of the tumor and myxoid
degeneration of the vessel wall are suggestive of infiltrative growth, no definitive vascular invasion is identified in the histologic sections
reviewed. Tumor proliferation extends into the ovarian capsule (arrows) without extra-capsular extension (c). Struma ovarii (d - upper left) and
squamous differentiation of the mature cystic teratoma (d - mid-lower right). Immunohistochemical stain for thyroid transcription factor (TTF-1) at
40× magnification with positive staining only in the areas of thyroid differentiation (e). a-d are hematoxylin and eosin stained with magnification
200× (a), 100× (b), and 40× (c, d)
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during pregnancy, the decision was made to delay fur-
ther testing and therapy until after delivery. Two months
after delivery, the patient underwent total thyroidectomy
to permit evaluation for metastatic disease and monitor-
ing for recurrence by Tg levels. The thyroid pathology
was benign.
Several months after delivery and cessation of lacta-
tion, the patient underwent L-T4 withdrawal and her Tg
unexpectedly rose from 0.8 ng/mL (TSH 5.8 mU/L) to
113.7 ng/mL (TSH 46 mU/L). A concurrent diagnostic
I-131 scan (1 mCi) with planar and SPECT/CT imaging
revealed focal central neck activity consistent with thy-
roid remnant and the presence of iodine-avid skeletal
metastatic disease involving the left ninth rib, bilateral
proximal femurs, and sacrum (Fig. 2A-F). Following
320 mCi I-131 therapy based on blood dosimetry calcu-
lations, post-therapy scan revealed the additional finding
of miliary pulmonary metastases (Fig. 2G). Due to
high-quality SPECT/CT images, separate dedicated CT
and bone scan were not necessary. She was subsequently
treated with TSH suppression resulting in an undetect-
able Tg < 0.1 ng/mL (TSH 0.02 mU/L). In order to assess
the interval response to I-131 treatment, follow-up
evaluation after L-T4 withdrawal protocol was obtained
nine months later, demonstrating a stimulated Tg of
0.2 ng/mL (TSH 36.4 mU/L) and negative diagnostic
I-131 scan without focal abnormal radioiodine uptake in
the neck or skeleton. As she was planning for a second
pregnancy and her pulmonary disease was not visible on
the prior diagnostic I-131 scan but became apparent only
on the post-therapy scan, a 100 mCi I-131 therapeutic
challenge was performed to eliminate any microscopic re-
sidual disease and more accurately ascertain the treatment
response. The post-therapy I-131 scan demonstrated
complete resolution of pulmonary metastatic disease;
however, faint residual foci of activity were demonstrated
in the left ninth rib, sacrum, and left proximal femur, con-
sistent with a partial therapeutic response in the skeleton
(Fig. 2I-N). Eight months later, Tg was < 0.1 ng/mL (TSH
0.02 mU/L). The patient continues to do well, being con-
servatively managed with active clinical and biochemical
monitoring during L-T4 suppression therapy.
Discussion
There are no established diagnostic and therapeutic
approaches for the management of malignant struma
Fig. 2 Nuclear medicine imaging at initial evaluation and subsequent follow-up of metastatic struma ovarii. Diagnostic 131-I planar scan,
posterior view (a) demonstrates central neck activity and abnormal activity in the left hemithorax, central pelvis and bilateral proximal femurs.
Diagnostic SPECT/CT demonstrates thyroid remnant tissue in the thyroidectomy bed (b) and skeletal metastatic disease localized to left 9th rib
(c), sacrum (d) and bilateral proximal femurs (e, f). Post-therapy 131-I planar scan, posterior view (g) demonstrates diffuse lung activity consistent
with miliary pulmonary metastases in addition to focal central neck activity and skeletal metastatic foci. Follow-up diagnostic planar 131-I scan,
posterior view (h) demonstrates physiologic radiotracer activity in the stomach, and urinary activity in the right renal collecting system and
bladder, without foci of abnormal activity. Post-therapy 131-I scan, posterior view (i) obtained after 100 mCi therapeutic challenge ascertained
resolution of pulmonary miliary metastatic disease, but residual foci of activity were demonstrated in the left hemithorax and pelvis and
confirmed on SPECT/CT in the left ninth rib (k), sacrum (l), and left proximal femur (n) consistent with a partial therapeutic response in the
skeleton. Focal sclerosis without focal 131-I uptake is demonstrated in the right femoral neck, consistent with treatment response and bone
healing (m). Complete therapeutic response is demonstrated in the thyroidectomy bed (j)
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ovarii. While some other authors advocate for total hys-
terectomy and bilateral salpingo-oophorectomy in the
setting of metastatic disease [2, 8], only a unilateral
salpingo-oophorectomy was performed in this case due
to the patient’s desire for future fertility and unclear
benefit of more extensive resection. A series of 53 pa-
tients demonstrated that independent of surgical ap-
proach, recurrence rates were only 7.5% at 25 years for
malignant struma ovarii, although the patients did not
have known metastatic disease at diagnosis, follow-up
was often markedly less than 25 years, and staging and
management strategies were variable [2]. The authors
recommended a risk stratification approach in which pa-
tients with gross extra-ovarian extension, distant metas-
tases at diagnosis, or concurrent primary thyroid gland
cancer receive total thyroidectomy and radioactive iod-
ine while others receive pelvic surgery alone. Potential
concerns with this approach include the limited ability
to identify distant metastases without thyroidectomy and
I-131 scan, difficulty monitoring for local recurrence in
the pelvis (as opposed to the neck for primary thyroid
gland cancer), and limited data regarding long-term
follow-up and risk of recurrence.
Total thyroidectomy in this patient permitted diagnos-
tic scintigraphic evaluation which identified distant
metastatic disease to the skeleton and guided I-131
treatment based on blood dosimetry calculations. The
decision to perform thyroidectomy and aggressively
evaluate for metastatic disease was made given the lack
of high quality data on the risk for metastases in this
rare condition and the difficulty monitoring for local re-
currence or residual disease in the pelvis. Additionally,
the presence of multiple mitotic figures on histopath-
ology review indicated rapid tumor growth, which may
be associated with decreased survival in thyroid cancer
arising from the thyroid gland [9, 10]. The association
between mitotic figures and increased risk has not been
shown with struma ovarii, although studies are limited
by small sample size with the largest study (n = 86)
showing ≥1 mitosis per ten high powered fields (HPF) in
42% of biologically benign struma ovarii vs. 57% of ma-
lignant struma ovarii (p = 0.22) [4]. Furthermore, studies
have shown that the histologic features that increase the
risk of malignant behavior in this class of tumors include
size of the struma ovarii greater than 5 cm and the pres-
ence of greater than 50% of the teratoma containing pro-
liferating thyroid tissue, both of which were present in
this case [11].
While the preablation stimulated Tg of 113.7 ng/mL is
quite elevated and consistent with distant metastatic dis-
ease based on proposed cutoff of 47.1 ng/mL [12], it
may be lower than expected given the extent of meta-
static disease involving the lungs and bone, as other
studies have found that Tg > 215 ng/mL is more likely
with this extent of disease [13]. Additionally, the second
preablation stimulated Tg of 0.2 ng/mL with bony me-
tastases may be lower than expected. These findings
raise the possibility that this tumor has reduced
efficiency for producing Tg which can be seen in
de-differentiated thyroid cancers [14]. However, the focal
I-131 uptake within the metastatic lesions demonstrated
on scans argues that the tumor remains differentiated,
maintaining its capacity to concentrate therapeutic
I-131. Thyroid cancers have demonstrated variability in
Tg production, and therefore correlation of stimulated
Tg levels with scintigraphy findings has been used for
guiding therapeutic I-131 administration [15].
In patients with cancer in the thyroid gland, SPECT/
CT imaging has been shown to be helpful in providing
anatomic correlate for planar scintigraphy findings and
accurate localization of metastatic disease [16], as was
true in this case. An important caveat with the use of
diagnostic I-131 scintigraphy is the risk of false reassur-
ance due to the low I-131 activity (1–2 mCi) used for
diagnostic purposes. The post-therapy scan can provide
additional information regarding the presence of metas-
tases and response to therapy [17]. In this case, the pul-
monary metastases were initially not evident on
diagnostic whole body I-131 scan but became apparent
on the post-therapy scan. Subsequent follow-up evalu-
ation with a diagnostic I-131 scan was negative for dis-
ease persistence, and the stimulated Tg was only 0.2 ng/
ml; however, the second post-therapy scan showed only
partial therapeutic response in the skeleton. This high-
lights the importance of integrating all clinical, histo-
pathology, laboratory and diagnostic and post-therapy
imaging information for clinical decision making in the
management of advanced and metastatic thyroid cancer.
An interesting aspect of this case is the clinical presen-
tation of malignant struma ovarii during pregnancy and
the patient’s desire for further fertility. Estrogen is
known to be a stimulator of benign and malignant thy-
roid cells in vitro [18]. As has been shown in breast can-
cer, estrogen may impact adhesion, invasion, migration
and angiogenesis in thyroid cancer and it is known that
estrogen and progesterone receptors are present in pap-
illary thyroid cancer cells [18, 19]. Recent pregnancy
may be associated with a transient increased risk of thy-
roid cancer although data are limited [20, 21]. hCG is
known to stimulate TSH receptors and may also pro-
mote tumor growth during pregnancy [22]. In this case,
it is possible that the patient’s pregnancy contributed to
the increased size of the tumor, and thus the discovery
was made during pregnancy rather than prior to concep-
tion. The patient was counseled regarding the possible
increased risk during subsequent pregnancies, although
her continued undetectable Tg under L-T4 suppression
is encouraging that she will do well. No further imaging
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has been performed to date since a conservative man-
agement strategy has been chosen based on the patient’s
and treating endocrinologist’s preference. Although her
tumor may inefficiently produce Tg, the very low stimu-
lated Tg < 0.2 ng/mL (TSH 36.4 mU/L) obtained prior to
the second therapeutic I-131 administration and the cur-
rently undetectable TSH-suppressed Tg are reassuring.
Considering the risks for equivocal or indeterminate re-
sults with PET/CT imaging at very low Tg levels or non-
specific findings on bone scan, and given the unclear
benefit of further aggressive treatment in the current
clinical and biochemical context, the plan is for conser-
vative management with clinical and biochemical moni-
toring with serial Tg testing during L-T4 suppression;
further I-131 therapy remains possible if justified by bio-
chemical evidence of recurrence and/or progression dur-
ing long-term clinical surveillance.
Conclusions
This unusual case presents important considerations in
the care of patients with malignant struma ovarii. First,
staging with a diagnostic whole body radioiodine scan
and stimulated Tg level following thyroidectomy needs
to be considered in all patients with intermediate and
high-risk histopathology findings. Second, the I-131 scan
should include SPECT/CT imaging, which can demon-
strate additional areas of metastases missed on planar
imaging, allows for accurate anatomic correlation of
metastatic lesions, and can impact treatment decisions
[16]. Third, when I-131 treatment is given, a
post-therapy I-131 scan should always be obtained
two-seven days after treatment to assess for additional
findings as compared with the diagnostic I-131 scan
[17]. Finally, the role of sex hormones and hCG in thy-
roid cancer arising from both struma ovarii and the thy-
roid gland should be explored further.
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